Our Services
Medical Information
Helpful Resources
Published on: 4/21/2026
Low dose naltrexone at 1.5–4.5 mg daily shows promising off-label potential for neuropathic pain by modulating microglial inflammation and boosting endorphin rebound, with small studies reporting meaningful pain reductions and minimal sedation. Although most research is limited by small sample sizes, short follow-up, and the need for compounding and monitoring, LDN may offer relief when first-line treatments fail or cause intolerable side effects.
There are several factors to consider, so see below for complete details on dosing strategies, benefits, risks and next steps under medical supervision.
Neuropathic pain—often described as burning, tingling, or electric shocks—is caused by damage or dysfunction in the nerves. Conditions such as diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy and other chronic nerve injuries can be debilitating. Standard treatments (antidepressants, anticonvulsants, topical agents, opioids) help many people but can fall short or cause troublesome side effects.
In recent years, low dose naltrexone for neuropathy has emerged as an "off-label" option. Originally approved at 50 mg–100 mg to treat opioid and alcohol dependence, naltrexone at much lower doses (typically 1.5 mg–4.5 mg daily) appears to modulate inflammation and pain signaling without blocking opioids. Below we explore the science, benefits, risks and practical considerations of using LDN for nerve pain.
• Naltrexone is an opioid receptor antagonist. At standard doses, it blocks the effects of opioids.
• LDN refers to doses 10–20 times lower (1.5 mg–4.5 mg).
• Prescribed "off-label" — meaning it's not FDA-approved for neuropathic pain, but physicians may legally prescribe it.
• Compounded by specialty pharmacies into capsules or liquids.
LDN's pain-relieving effects are distinct from traditional painkillers:
Research into low dose naltrexone for neuropathy is promising but still evolving. Key findings include:
• Small Randomized Trials
– Fibromyalgia study (n≈30): LDN 4.5 mg daily led to a 30% average pain reduction vs. placebo.
– Diabetic neuropathy pilot: significant decrease in burning pain scores over 8 weeks.
• Observational Studies
– Case series in chemotherapy-induced neuropathy reported up to 50% symptom improvement in some patients.
– Complex regional pain syndrome (CRPS) reports show pain relief in refractory cases.
• Mechanistic Studies
– Laboratory models confirm LDN's anti-inflammatory action on microglia and reduced nerve hypersensitivity.
Limitations:
• Small sample sizes
• Short follow-up durations (4–12 weeks)
• Lack of large, definitive Phase III trials
Overall, evidence supports LDN as a potential adjunct or alternative when standard therapies fail or cause intolerable side effects.
Low dose naltrexone is not a magic bullet, but it may offer relief for people who:
Before starting LDN:
If you're experiencing symptoms like burning, tingling, or shooting pain and want to understand whether you may have Neuropathic Pain, a free AI-powered symptom checker can help you assess your symptoms in just a few minutes.
Low dose naltrexone could be a valuable tool in your pain-management toolbox. If you and your physician decide to proceed:
Finally, remember that nerve pain can sometimes signal a serious underlying condition. Always speak to a doctor if you experience:
By partnering with a knowledgeable provider, you can determine if low dose naltrexone for neuropathy is right for you and integrate it safely into a comprehensive treatment plan.
(References)
* Patel, D., et al. (2023). Low-dose naltrexone in the treatment of chronic pain conditions: A systematic review and meta-analysis of randomized controlled trials. *European Journal of Pain, 27*(7), 785-802.
* Mendelsohn, A. E., & Mendelson, A. A. (2021). Low-dose naltrexone: A promising treatment in chronic pain. *PM&R, 13*(5), 577-585.
* Boland, S. M., & Johnson, D. (2018). Low-dose naltrexone for the treatment of chronic pain: A comprehensive review. *Journal of Pain Research, 11*, 2909-2919.
* Patel, R., et al. (2021). Role of Low-Dose Naltrexone in the Management of Chronic Pain: A Narrative Review. *Journal of Clinical Pharmacology and Therapeutics, 46*(1), e6-e17.
* Crews, K. R., et al. (2023). Effectiveness of low-dose naltrexone in the treatment of chronic primary pain: a double-blind, randomized, placebo-controlled trial. *Pain Reports, 8*(5), e1102.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.